Product Images Terbinafine
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 3 images provide visual information about the product associated with Terbinafine NDC 69097-859 by Cipla Usa Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
image - 250mg 30tabs
These are Terbinafine tablets, USP containing 250mg of Terbinafine HCI. The tablets are dispensed with a patient information leaflet attached. The recommended storage temperature is between 20°C to 25°C. The tablets are manufactured by InvaGen Pharmaceuticals under Cipla Ltd. and distributed by Cipla USA, Inc. The lot number is not readable.*
Image 2 - terbinafine str
Image 1 - terbinafine table
This is a table presenting adverse events and discontinuation in a clinical trial comparing Terbinafine tablets with Placebo. The trial assesses the frequency of different adverse events such as headache, gastrointestinal symptoms (diarrhea, dyspepsia, abdominal pain, nausea, among others), dermatological symptoms (rash, pruritus, utticaria, among others), liver enzyme abnormalities, taste disturbance, and visual disturbance. The table reports the percentages of individuals experiencing each adverse event for both the Terbinafine and Placebo groups.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
